REGENXBIO Inc.
RGNXClinical-stage biotechnology company developing AAV gene therapies
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
4 upcoming, 1 past
How RGNX's past catalysts played out
No drugs found in this phase.
Wet AMD and Diabetic Retinopathy
1 drug in this indication
Duchenne muscular dystrophy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
When is REGENXBIO Inc.'s next FDA catalyst?→
REGENXBIO Inc.'s (RGNX) next tracked catalyst is a Phase 3 expected January 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RGNX biotech catalysts?→
Add RGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REGENXBIO Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.